We have developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases.
Our proprietary, synergistic toolkit allows us to precisely:
RNA
WITHOUT
LIMITS
The field of RNA medicine holds limitless, untapped potential to rewrite the underlying basis of disease.
RNA medicines are currently limited by delivery to tissue targets and the absence of an integrated therapeutic platform
ReNAgade aims to overcome the limitations of RNA medicines by applying our comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale.
01 DELIVER
ReNAgade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells
01 DELIVER
ReNAgade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells
02 CODE
Reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics
01 DELIVER
ReNAgade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells
02 CODE
Reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics
03 EDIT
Enabling curative therapies by permanently correcting defective genes with proprietary technology
01 DELIVER
ReNAgade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells
02 CODE
Reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics
03 EDIT
Enabling curative therapies by permanently correcting defective genes with proprietary technology
04 INSERT
Industry leading all-RNA system to enable exon or large gene insertions as a Gene Therapy 2.0 platform
01 DELIVER
ReNAgade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells
02 CODE
Reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics
03 EDIT
Enabling curative therapies by permanently correcting defective genes with proprietary technology
04 INSERT
Industry leading all-RNA system to enable exon or large gene insertions as a Gene Therapy 2.0 platform
For the first time, RNA medicines have the potential to treat any disease, anywhere in the body
A MODEL CODED FOR SUCCESS
POWERFUL POSITIONING
- $300M invested in ReNAgade, giving it the largest Series A funding round of 2023
- Backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market
- Joint Venture with Orna Therapeutics, to combine ReNAgade’s delivery platform with Orna’s circular RNA technology
BEST-IN-CLASS TECH IN-HOUSE
- Superior RNA targeting via a broad portfolio of novel delivery systems integrated with a synergistic RNA toolkit that delivers, codes, edits, and inserts, expanding the array of addressable diseases
FEARLESS TALENT
- Highly regarded and established executive leadership, responsible for bringing forward over 25 NDAs/ BLAs and 200+ IND/ CTAs
- Unsurpassed experience in pioneering RNA medicines and delivery technologies from discovery through clinical development
- Multidisciplinary research team and tools to rapidly develop technologies in translationally relevant models and species
BLA=biologics license application; CTA=clinical trial application; IND=investigational new drug; NDA=new drug application.
“RNA without limits”, “Deliver-Code-Edit-Insert” are trademarks of ReNAgade Therapeutics, Inc.